Fig. 1: Patient care pathway, detailing the median time between events from diabetes diagnosis to first treatment with intravitreal aflibercept (IVT-AFL). | Eye

Fig. 1: Patient care pathway, detailing the median time between events from diabetes diagnosis to first treatment with intravitreal aflibercept (IVT-AFL).

From: Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes

Fig. 1

Timeline data is outlined for both the treatment-naïve and non-treatment-naïve cohorts for the study eye (SE) and the fellow eye where applicable. d Days, DMO Diabetic macular oedema; y Years.

Back to article page